Mbx Biosciences Inc (MBX)

$14.40 -0.17 (-1.17%)
Market Cap 506.93M
Revenue (ttm) 0.00
Net Income (ttm) -61.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 215,000
Avg Vol 423,486
Day's Range N/A - N/A
Shares Out 33.59M
Stochastic %K 66%
Beta N/A
Analysts Strong Sell
Price Target $37.71

Company Profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a...

Industry: Biotechnology
Sector: Healthcare
Phone: (317) 659-0200
Website: mbxbio.com
Address:
11711 North Meridian Street, Suite 300, Carmel, United States
Eagley3k
Eagley3k Sep. 3 at 9:30 PM
0 · Reply
Eagley3k
Eagley3k Sep. 3 at 9:16 PM
$KAPA funny how some traders wanna short this $1.5 stock only because its up 200% YTD. first of all it had no business diving into penny land with block buster therapy that has huge market potential for more than one indication. your only bet is a bad outcome on PH2 efficacy results. with insiders owning 57% of this, I'm riding along for sure. nothing wrong fundamentally or technically here and is not a good short setup to be honest. I short stocks too. I just see upside return better than downside here. also check out $MBX due to report PH2 results this month as well. good company with good management team. has 50% insider ownership. IPO'd at $16 last year and up a lot this year with no dilution risk. GLTA.
0 · Reply
lukasgx
lukasgx Sep. 2 at 7:13 PM
$MBX just started position here today 🪬🤑
0 · Reply
TaxiBiotech_
TaxiBiotech_ Aug. 31 at 9:47 AM
🚕 Let’s go with $CRNX + $MREO + $MBX into year-end. We’ll see what happens in the end… Will these potential rockets reach the stratosphere, or come crashing back down to earth? 🚀🌍
0 · Reply
ps03
ps03 Aug. 18 at 3:01 PM
$MBX $30 in a month📈
0 · Reply
belugatrade
belugatrade Aug. 15 at 5:03 PM
$MBX wants to pop
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 12:30 PM
Jefferies has adjusted their stance on MBX Biosciences ( $MBX ), setting the rating to Buy with a target price of 36.
0 · Reply
The1lluminati
The1lluminati Aug. 13 at 4:24 PM
$RKT $GME $MBX and wait $SDG is 105% short???
0 · Reply
TickerVoice
TickerVoice Aug. 13 at 2:52 PM
$MBX is it risky in Sep? data out anytime? will it be delayed till last day?
0 · Reply
The1lluminati
The1lluminati Aug. 13 at 2:15 PM
$RKT 65% short float, $GME 16% short, $MBX 35% short with lots of initiations
0 · Reply
Latest News on MBX
Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 2:00 PM EDT - 20 days ago

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 7, 2025, 8:00 AM EDT - 27 days ago

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Jun 23, 2025, 8:00 AM EDT - 2 months ago

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

Jun 16, 2025, 8:00 AM EDT - 2 months ago

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

Jun 10, 2025, 8:00 AM EDT - 3 months ago

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

May 31, 2025, 7:24 AM EDT - 3 months ago

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

MBX Biosciences to Participate in June Investor Conferences

May 20, 2025, 8:00 AM EDT - 3 months ago

MBX Biosciences to Participate in June Investor Conferences

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 12, 2025, 8:00 AM EDT - 4 months ago

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

Apr 22, 2025, 8:00 AM EDT - 4 months ago

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 8:00 AM EDT - 5 months ago

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 17, 2025, 8:00 AM EDT - 6 months ago

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

MBX Biosciences Announces Additions to Leadership Team

Mar 5, 2025, 8:00 AM EST - 6 months ago

MBX Biosciences Announces Additions to Leadership Team

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Mar 3, 2025, 8:00 AM EST - 6 months ago

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

MBX Biosciences to Participate in March Investor Conferences

Feb 18, 2025, 8:00 AM EST - 7 months ago

MBX Biosciences to Participate in March Investor Conferences

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

Jan 7, 2025, 7:00 AM EST - 8 months ago

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Nov 18, 2024, 8:00 AM EST - 10 months ago

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

MBX Biosciences to Participate in Upcoming November Investor Conferences

Oct 28, 2024, 8:00 AM EDT - 11 months ago

MBX Biosciences to Participate in Upcoming November Investor Conferences

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

Sep 30, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 16, 2024, 4:05 PM EDT - 1 year ago

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Sep 14, 2024, 5:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

BCAX GLXG TDTH XCH ZBIO

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

Sep 13, 2024, 12:36 PM EDT - 1 year ago

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

MBX Biosciences raises $163.2 mln in US IPO

Sep 12, 2024, 7:20 PM EDT - 1 year ago

MBX Biosciences raises $163.2 mln in US IPO

MBX Biosciences Announces Pricing of Initial Public Offering

Sep 12, 2024, 7:11 PM EDT - 1 year ago

MBX Biosciences Announces Pricing of Initial Public Offering

MBX Biosciences Announces Launch of Initial Public Offering

Sep 9, 2024, 6:30 AM EDT - 1 year ago

MBX Biosciences Announces Launch of Initial Public Offering

MBX Biosciences IPO Registration Document (S-1)

Aug 23, 2024, 4:44 PM EDT - 1 year ago

MBX Biosciences IPO Registration Document (S-1)

Eagley3k
Eagley3k Sep. 3 at 9:30 PM
0 · Reply
Eagley3k
Eagley3k Sep. 3 at 9:16 PM
$KAPA funny how some traders wanna short this $1.5 stock only because its up 200% YTD. first of all it had no business diving into penny land with block buster therapy that has huge market potential for more than one indication. your only bet is a bad outcome on PH2 efficacy results. with insiders owning 57% of this, I'm riding along for sure. nothing wrong fundamentally or technically here and is not a good short setup to be honest. I short stocks too. I just see upside return better than downside here. also check out $MBX due to report PH2 results this month as well. good company with good management team. has 50% insider ownership. IPO'd at $16 last year and up a lot this year with no dilution risk. GLTA.
0 · Reply
lukasgx
lukasgx Sep. 2 at 7:13 PM
$MBX just started position here today 🪬🤑
0 · Reply
TaxiBiotech_
TaxiBiotech_ Aug. 31 at 9:47 AM
🚕 Let’s go with $CRNX + $MREO + $MBX into year-end. We’ll see what happens in the end… Will these potential rockets reach the stratosphere, or come crashing back down to earth? 🚀🌍
0 · Reply
ps03
ps03 Aug. 18 at 3:01 PM
$MBX $30 in a month📈
0 · Reply
belugatrade
belugatrade Aug. 15 at 5:03 PM
$MBX wants to pop
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 12:30 PM
Jefferies has adjusted their stance on MBX Biosciences ( $MBX ), setting the rating to Buy with a target price of 36.
0 · Reply
The1lluminati
The1lluminati Aug. 13 at 4:24 PM
$RKT $GME $MBX and wait $SDG is 105% short???
0 · Reply
TickerVoice
TickerVoice Aug. 13 at 2:52 PM
$MBX is it risky in Sep? data out anytime? will it be delayed till last day?
0 · Reply
The1lluminati
The1lluminati Aug. 13 at 2:15 PM
$RKT 65% short float, $GME 16% short, $MBX 35% short with lots of initiations
0 · Reply
The1lluminati
The1lluminati Aug. 13 at 2:12 PM
$GME $MBX today
0 · Reply
judgeyoung2
judgeyoung2 Aug. 7 at 8:17 PM
$MBX
0 · Reply
JarvisFlow
JarvisFlow Aug. 5 at 11:30 AM
Mizuho has updated their rating for MBX Biosciences ( $MBX ) to Outperform with a price target of 38.
0 · Reply
JxP2000
JxP2000 Jul. 30 at 7:15 PM
$MBX oh, pretty dead in here... was just looking to see what is in the pipeline near term for this company. As in next month.
0 · Reply
StockScanners
StockScanners Jul. 25 at 5:50 PM
$MBX needs to hold above 14
0 · Reply
Duckboy65
Duckboy65 Jul. 21 at 4:11 PM
$MBX Target $40-Buy at Stifel
0 · Reply
burningmoneyagain
burningmoneyagain Jul. 16 at 1:23 PM
$MBX anyone here?
0 · Reply
jmalone13
jmalone13 Jun. 26 at 1:38 PM
$MBX the latest hire in the news sounds like they are preparing for some good things coming out of their leading 2nd phase product. The platform looks good here for developing beneficial and profitable drugs.
0 · Reply
PenkeTrading
PenkeTrading Jun. 4 at 1:56 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of MBX Biosciences, Inc. Common Stock. Is that bullish or bearish? $MBX #RsiOverbought #NASDAQ
0 · Reply
BioTechHealthX
BioTechHealthX May. 30 at 2:55 PM
$MBX is developing next-generation endocrine treatments with fewer side effects and better patient outcomes. https://biotechhealthx.com/biotech-news/mbx-biosciences-is-building-the-future-of-hormone-therapy/
0 · Reply
ChartChartist
ChartChartist May. 3 at 4:38 PM
$MBX up ery day $CDT everyone making piles of money each day $BNZI handle formed 👁️ $JDZG gonna run at 4am , get that trade in
0 · Reply
Quantumup
Quantumup May. 2 at 3:08 PM
JPMorgan⬆️the PT on $ASND to $245 from $200 and reiterated at an Overweight. $AZN $MBX $NVO $BBIO JPMorgan said in its note: "Coming off of $ASND's 1Q results and our conversations with mgmt, we are even more confident in Yorvipath's trajectory and believe the strong rev number of €44.7mm which came in ~50% above JPMe/cons will lead to continued upside in the stock. We think Yorvi has legs to run and we are raising our 2025-2030 WW Yorvipath estimates by 27-53% and our price target to $245 from $200."
0 · Reply